This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Capitol Health Future Growth

Future criteria checks 4/6

Capitol Health is forecast to grow earnings and revenue by 68.4% and 6.4% per annum respectively. EPS is expected to grow by 68.5% per annum. Return on equity is forecast to be 15.1% in 3 years.

Key information

68.4%

Earnings growth rate

68.5%

EPS growth rate

Healthcare earnings growth	23.7%
Revenue growth rate	6.4%
Future return on equity	15.1%
Analyst coverage	Good
Last updated	17 Oct 2024

Recent future growth updates

Recent updates

Capitol Health Limited's (ASX:CAJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Mar 05

Have Insiders Been Selling Capitol Health Limited (ASX:CAJ) Shares This Year?

Feb 14

Did You Miss Capitol Health's (ASX:CAJ) 20% Share Price Gain?

Jan 19

Is Capitol Health Limited's (ASX:CAJ) Shareholder Ownership Skewed Towards Insiders?

Dec 22

Capitol Health Limited's (ASX:CAJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Dec 01

Here's Why We Don't Think Capitol Health's (ASX:CAJ) Statutory Earnings Reflect Its Underlying Earnings Potential

Aug 17

Is Now An Opportune Moment To Examine Capitol Health Limited (ASX:CAJ)?

Jul 25

Is Capitol Health Limited's (ASX:CAJ) Latest Stock Performance A Reflection Of Its Financial Health?

Jul 04

Earnings and Revenue Growth Forecasts

ASX:CAJ - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2027	284	19	21	50	7
6/30/2026	270	15	19	45	8
6/30/2025	252	13	15	39	8
6/30/2024	235	-15	17	36	N/A
3/31/2024	232	-5	14	36	N/A
12/31/2023	229	6	12	36	N/A
9/30/2023	219	-3	16	37	N/A
6/30/2023	210	-12	21	37	N/A
3/31/2023	198	-12	18	33	N/A
12/31/2022	187	-12	16	28	N/A
9/30/2022	186	-1	18	30	N/A
6/30/2022	184	11	19	32	N/A
3/31/2022	186	12	22	34	N/A
12/31/2021	188	14	26	36	N/A
9/30/2021	183	13	29	39	N/A
6/30/2021	178	12	33	41	N/A
3/31/2021	168	8	33	43	N/A
12/31/2020	159	4	34	45	N/A
9/30/2020	156	3	28	40	N/A
6/30/2020	154	1	23	35	N/A
3/31/2020	156	8	18	30	N/A
12/31/2019	157	15	12	25	N/A
9/30/2019	153	20	8	22	N/A
6/30/2019	149	24	4	18	N/A
12/31/2018	137	-2	5	15	N/A
9/30/2018	128	-6	4	13	N/A
6/30/2018	119	-11	4	11	N/A
12/31/2017	110	2	N/A	15	N/A
9/30/2017	108	2	N/A	15	N/A
6/30/2017	107	2	N/A	15	N/A
12/31/2016	80	1	N/A	13	N/A
9/30/2016	92	2	N/A	13	N/A
6/30/2016	104	2	N/A	13	N/A
3/31/2016	148	-2	N/A	15	N/A
12/31/2015	139	1	N/A	13	N/A
9/30/2015	125	3	N/A	14	N/A
6/30/2015	110	4	N/A	16	N/A
3/31/2015	103	6	N/A	16	N/A
12/31/2014	95	9	N/A	16	N/A
9/30/2014	92	8	N/A	14	N/A
6/30/2014	90	7	N/A	12	N/A
3/31/2014	83	6	N/A	10	N/A
12/31/2013	77	5	N/A	7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CAJ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: CAJ is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CAJ is expected to become profitable in the next 3 years.

Revenue vs Market: CAJ's revenue (6.4% per year) is forecast to grow faster than the Australian market (5.8% per year).

High Growth Revenue: CAJ's revenue (6.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CAJ's Return on Equity is forecast to be low in 3 years time (15.1%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/11 08:46
End of Day Share Price	2024/12/11 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Capitol Health Limited is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Russell Wright	Barclay Pearce Capital Pty Limited
Andrew Hodge	Credit Suisse
Daniel Downes	Goldman Sachs

This company listing is no longer active

Capitol Health Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target increased by 7.1% to AU$0.31

Capitol Health Limited Provides Earnings Guidance for the Year 2025

Price target decreased by 9.8% to AU$0.28

Price target decreased by 9.6% to AU$0.33

Price target increased to AU$0.43

Consensus EPS estimates fall by 12%

Recent updates

Integral Diagnostics Limited (ASX:IDX) completed the acquisition of Capitol Health Limited (ASX:CAJ).

Insufficient new directors

Capitol Health Limited, Annual General Meeting, Feb 28, 2025

Final dividend of AU$0.004 announced

Price target increased by 7.1% to AU$0.31

Full year 2024 earnings released: AU$0.014 loss per share (vs AU$0.011 loss in FY 2023)

Capitol Health Limited Provides Earnings Guidance for the Year 2025

Capitol Health Limited to Report Fiscal Year 2024 Results on Aug 22, 2024

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Integral Diagnostics Limited (ASX:IDX) agreed to acquire Capitol Health Limited (ASX:CAJ) for approximately AUD 350 million.

Calculating The Fair Value Of Capitol Health Limited (ASX:CAJ)

Now 21% undervalued after recent price drop

Now 21% undervalued

First half dividend of AU$0.005 announced

First half 2024 earnings released: EPS: AU$0.002 (vs AU$0.015 loss in 1H 2023)

New major risk - Financial position

Now 20% undervalued

Capitol Health Limited to Report First Half, 2024 Results on Feb 29, 2024

Capitol Health Limited Appoints Brendon Pentland as the Chief Financial Officer, Effective 1 April 2024

Capitol Health Limited's (ASX:CAJ) Popularity With Investors Is Clear

Capitol Health (ASX:CAJ) Takes On Some Risk With Its Use Of Debt

Now 21% undervalued

Now 21% undervalued after recent price drop

Capitol Health Limited Announces the Resignation of Craig Bremner as Chief Financial Officer

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Price target decreased by 9.8% to AU$0.28

Capitol Health Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings: EPS misses analyst expectations

Capitol Health Limited to Report Fiscal Year 2023 Results on Aug 24, 2023

Price target decreased by 9.6% to AU$0.33

Capitol Health Limited to Report First Half, 2023 Results on Feb 23, 2023

Now 21% undervalued

Now 21% undervalued

Capitol Health Limited (ASX:CAJ) completed the acquisition of Future Medical Imaging Group Pty Ltd.

Is Capitol Health Limited (ASX:CAJ) Worth AU$0.3 Based On Its Intrinsic Value?

Capitol Health Limited Declares Franked Dividend for the Six Months Ended June 30, 2022, Payable on October 21, 2022

Price target increased to AU$0.43

Capitol Health Limited, Annual General Meeting, Nov 15, 2022

Full year 2022 earnings: EPS misses analyst expectations

Capitol Health Limited Announces Dividend for the Six Months Ended June 30, 2022, Payable on 21 October, 2022

Consensus EPS estimates fall by 12%

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Capitol Health Limited Announces Dividend for the Six Months Ended December 31, 2021, Payable on April 1, 2022

Capitol Health Limited to Report First Half, 2022 Results on Feb 24, 2022

Full year 2021 earnings released: EPS AU$0.012 (vs AU$0.001 in FY 2020)

Capitol Health (ASX:CAJ) Seems To Use Debt Rather Sparingly

Should You Investigate Capitol Health Limited (ASX:CAJ) At AU$0.37?

Capitol Health Limited's (ASX:CAJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Analysts increase EPS estimates to AU$0.012

First half 2021 earnings released: EPS AU$0.006 (vs AU$0.004 in 1H 2020)

Price target raised to AU$0.36

New 90-day high: AU$0.34

Have Insiders Been Selling Capitol Health Limited (ASX:CAJ) Shares This Year?

Capitol Health Limited (ASX:CAJ) acquired Direct Radiology.

Capitol Health Limited to Report First Half, 2021 Results on Feb 24, 2021

New 90-day high: AU$0.28

Did You Miss Capitol Health's (ASX:CAJ) 20% Share Price Gain?

Is Capitol Health Limited's (ASX:CAJ) Shareholder Ownership Skewed Towards Insiders?

Capitol Health Limited's (ASX:CAJ) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?

Price target raised to AU$0.31

Capitol Health Limited (ASX:CAJ) entered into a binding agreement to acquire Direct Radiology for AUD 12 million.

Capitol Health Limited (ASX:CAJ) entered into a binding agreement to acquire Direct Radiology for AUD 12 million.

New 90-day high: AU$0.27

Capitol Health Limited Appoints Craig Bremner as Chief Financial Officer, November 9, 2020

Capitol Health Limited Announces Resignation of Marcell Judkins as Chief Financial Officer

Price target raised to AU$0.27

Capitol Health Limited (ASX:CAJ) completed the acquisition of 90% stake in Fowler Simmons Radiology.